Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Adverse Events during Immunotherapy against Grass Pollen-Induced Allergic Rhinitis - Differences between Subcutaneous and Sublingual Treatment

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Research output: Contribution to journalReviewResearchpeer-review

  4. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Unique Aspects of Asthma in Women

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Challenges in conducting paediatric trials with off-patent drugs

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hormone Replacement Therapy and Development of New Asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Allergic rhinitis triggered by grass pollen is a common disease, affecting millions of people worldwide. Treatment consists of symptom-alleviating drugs, such as topical corticosteroids or antihistamines. Another option is potentially curative immunotherapy, currently available as sublingual and subcutaneous treatment. We investigated the potential differences in the prevalence and severity of adverse events related to subcutaneous and sublingual immunotherapy against grass pollen-induced allergic rhinitis. A thorough literature search was performed using PubMed and EMBASE. The findings were compared with the available summaries of product characteristics and with commercial pharmacology databases (Micromedex). The majority of available safety data originates from registered products of standardized allergens. A surprisingly large percentage of drugs, especially those used in the United States, have no systematically collected safety data. No sufficiently powered randomized trials comparing sublingual and subcutaneous immunotherapy were available, but general safety assessments indicate that sublingual tablet treatment is safer than subcutaneous treatment. Not all commonly used immunotherapy drugs are officially registered and not all have systematically collected safety data. This is especially true for older drugs used in the United Stages. In contrast, newer drugs that have undergone extensive clinical testing have better documentation, but unified collection of safety data is still lacking. Considering the evidence available, most drugs elicit similar side effects from the same organ systems, and symptoms from the sublingual drug classes are probably less severe. However, a head-to-head comparison of safety and efficacy is lacking. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Volume117
Issue number2
Pages (from-to)73-84
Number of pages11
ISSN1742-7843
DOIs
Publication statusPublished - Aug 2015

ID: 45344854